Expanded Access Policy

Expanded access, also known as compassionate use, is a potential pathway for patients with an immediately life-threatening condition or serious disease to gain access to an investigational drug or other medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

Latus is committed to developing safe and effective therapies for patients and strives to put patients first. Our goal is to provide gene therapies to patients as soon as possible through efficient drug development.

At this time, Latus does not offer Expanded Access for our investigational gene therapies. Patients and health care providers who are interested in our investigational products may learn more about our applicable clinical trials, when available, by visiting clinicaltrials.gov and searching for Latus.

If you are a healthcare provider with questions about our clinical trials, please submit a request to: info@latusbio.com. We acknowledge questions as soon as possible, usually within 5 business days of receipt.

Latus will continue to evaluate expanded access opportunities as our efforts advance, and we reserve the right to update this policy at any time.